Fidelity Investments
CTNM

Fidelity Investments’s Contineum Therapeutics CTNM Stock Holding History

Fidelity Investments’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6M Hold
814,871
– – ﹤0.01% 2023
2025
Q4 		$9.31M Hold
814,871
– – ﹤0.01% 2054
2025
Q3 		$9.57M Sell
814,871
-28,279
-3% -$228K ﹤0.01% 2019
2025
Q2 		$3.35M Buy
843,150
+32,833
+4% +$143K ﹤0.01% 2308
2025
Q1 		$5.66M Buy
810,317
+118,436
+17% +$1.08M ﹤0.01% 2103
2024
Q4 		$10.1M Sell
691,881
-5,046
-0.7% -$79.9K ﹤0.01% 1932
2024
Q3 		$13.3M Buy
696,927
+373,327
+115% +$7.16M ﹤0.01% 1836
2024
Q2 		$5.7M Buy
+323,600
New +$5.21M ﹤0.01% 2041

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments's CTNM Position: Q1 2026 in Review

Fidelity Investments held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 814,871 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2023.

Fidelity Investments first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $13.3M in Q3 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Fidelity Investments held 814,871 shares of Contineum Therapeutics worth $10.6M as of Q1 2026.
  • Fidelity Investments left its Contineum Therapeutics share count unchanged in Q1 2026.
  • Contineum Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2023 holding.
  • Fidelity Investments first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Fidelity Investments's Contineum Therapeutics position peaked at $13.3M in Q3 2024.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.